A U.S. Food and Drug Administration (FDA) advisory committee recently determined that phenylephrine, an ingredient commonly used to treat sinus and nasal congestion, is ineffective in treating these symptoms. This was apparent from research for years, yet large...
News
Latest News
Rubio Habla en La Poderosa
El senador estadounidense Marco Rubio (R-FL) habló con César Grajales de La Poderosa 670 AM en El Panorama Político, sobre la crisis fronteriza, sobre cómo los hispanoamericanos se ven afectados con la realidad del país, sobre los cargos contra el senador Bob Menéndez...
Rubio, Colleagues Reintroduce Bill to Protect Rights of Pregnant Students
Pregnant students are sometimes discriminated against by their schools, either intentionally or unintentionally and there is a concerning lack of awareness about the resources and rights available to them. Due to a lack of services and discrimination, these women may...
Rubio, Colleagues Reintroduce Intelligence Community Workforce Agility Protection Act
Currently, intelligence community civilians are subject to certain tax penalties for job-related relocation requirements, but active-duty military servicemembers are not subjected to the same penalties. These tax benefits, including the ability to deduct moving...
Rubio Delivers Remarks at Senate Intelligence Hearing
Vice Chairman of the Senate Select Committee on Intelligence Marco Rubio (R-FL) delivered opening remarks and questioned witnesses at a hearing on countering China’s influence in the United States. Watch Rubio’s opening remarks here as well as Part I and Part II of...
Rubio-led Resolution to Raise Awareness for Spinal Cord Injuries Passes Senate
Approximately 302,000 Americans live with spinal cord injuries. To help these people achieve a better quality of life, there is a need to increase education and invest in research. U.S. Senators Marco Rubio (R-FL) and Tammy Baldwin (D-WI) successfully led a bipartisan...
Rubio, Rosen Reintroduce Bipartisan Legislation to Study the Full Health Impacts of Covid-19
Washington, D.C. — U.S. Senators Marco Rubio (R-FL) and Jacky Rosen (D-NV) reintroduced the bipartisan Ensuring Understanding of COVID-19 to Protect Public Health Act, legislation that would direct the National Institutes of Health (NIH) to conduct a longitudinal study on mild, moderate, and severe cases of COVID-19 to ensure we gain a full understanding of both the short and long-term health impacts of the novel coronavirus. Rubio and Rosen first introduced the legislation in May 2020.
“As our nation continues to battle the coronavirus pandemic, it is critical that our health care experts at the NIH conduct a comprehensive study to help guide physicians caring for patients with COVID-19,” Rubio said. “There are still numerous unknowns about COVID-19, including its potential long-term health impacts, and this bipartisan bill provides the NIH with important guidelines to study this virus.”
“As our country continues to battle this virus, we must ensure we continue to examine all aspects of how COVID-19 affects patients from diverse populations,” Rosen said. “By focusing our nation’s efforts toward understanding the short and long-term health ramifications of COVID-19, we can arm our researchers and medical professionals with the most accurate data as they work to provide better treatment and vaccines for patients. I will continue working to protect the health of Nevadans during this unprecedented time.”
Background: More specifically, the bipartisan Ensuring Understanding of COVID-19 to Protect Public Health Act would direct the NIH to:
-
Conduct a nationwide study of the health outcomes and symptoms of COVID-19, including long-term impact on lung function and immune response, and the impact of treatments.
-
The study would include a wide variety of patients, to ensure diversity among race, ethnicity, geography, age, gender, and underlying health conditions; and
-
Monitor mental health outcomes.
-
The goal of the study is to gain a full understanding of both the short-term and long-term health impacts of COVID-19.
The findings would be released publicly every 3 months for the first two years, and every 6 months thereafter.